Clinical Trial Update: Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study to determine the maximum tolerated dose of PARPi 2X-121 as a monotherapy and in combination with dovitinib in patients with advanced solid tumors;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• 2X-121
• Dovitinib (dovitinib)

Snippet

Sponsor: Allarity Therapeutics | Conditions: Advanced Solid Tumors | Phase 1 | Status: SUSPENDED